• PRO20 PROJECT HERCULES: A PARADIGM SHIFT IN THE DEVELOPMENT OF COST-EFFECTIVENESS MODELS IN RARE DISEASES

    Nov 1, 2019, 00:00

  • PNS127 THE DEVELOPMENT OF CHIMERIC ANTIGEN RECEPTOR (CAR-T) CELL THERAPY IN CHINA

    Nov 1, 2019, 00:00

  • PCN448 IMPROVING THE ACCURACY AND REDUCING UNCERTAINTY OF PROBABILISTIC PARTITIONED SURVIVAL ANALYSES, BY CONSIDERING THE RELATIONSHIP BETWEEN PFS AND OS

    Nov 1, 2019, 00:00

  • PRS64 CONTENT VALIDATION OF THE RESPIRATORY SYMPTOMS SUBSCALE (RSS) OF THE QUALITY OF LIFE QUESTIONNAIRE-BRONCHIECTASIS (QOL-B) IN NON-CYSTIC FIBROSIS BRONCHIECTASIS (NON-CF BE)

    Nov 1, 2019, 00:00

  • PNS131 DO THE EVOLVING MARKET ACCESS POLICY DYNAMICS AND INCREASING IMPORTANCE OF CLINICAL AND HEALTH ECONOMIC EVIDENCE REPRESENT THE NEXT BIG OPPORTUNITY FOR PHARMA TO DEMONSTRATE VALUE IN CHINA?

    Nov 1, 2019, 00:00

  • PRS36 EPIDEMIOLOGICAL AND CLINICAL FEATURES OF HMPV AND RSV INFECTIONS AMONG CHILDREN HOSPITALIZED FROM ACUTE RESPIRATORY INFECTIONS IN MACAO: A RETROSPECTIVE STUDY FROM 2014 TO 2017

    Nov 1, 2019, 00:00

  • PMS48 270-DAYMORTALITY AND ITS PREDICTORS IN MEN WITH CONTRALATERAL HIP FRACTURE AFTER FEMORAL NECK FRACTURE

    Nov 1, 2019, 00:00

  • PCN493 PERCEPTIONS OF AND PARTICIPATION IN REAL-WORLD EVIDENCE RESEARCH AMONG US COMMUNITY ONCOLOGISTS

    Nov 1, 2019, 00:00

  • PCV102 PRESCRIPTION PATTERN EUROPE

    Nov 1, 2019, 00:00

  • PCN91 COST-EFFECTIVENESS OF IMMUNOTHERAPY-BASED DRUG REGIMENS FOR THE INITIAL TREATMENT OF PATIENTS WITH METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

    Nov 1, 2019, 00:00

  • PMU60 INCENTIVE STRUCTURES OF ADDITIONAL PAYMENTS FOR NEW TECHNOLOGIES IN INPATIENT CARE: DOES IT WORK?

    Nov 1, 2019, 00:00

  • PCN392 UTILISATION OF REAL-WORLD EVIDENCE IN THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE SUBMISSIONS OF THE TOP 20 ONCOLOGY DRUGS

    Nov 1, 2019, 00:00

  • PMH21 COST-EFFECTIVENESS OF THE PREDICT TEST: RESULTS AND LESSONS LEARNED FROM A EUROPEAN MULTINATIONAL DEPRESSION TRIAL

    Nov 1, 2019, 00:00

  • PDB54 ECONOMIC EVALUATION OF A NEW POLYGENIC RISK SCORE TO PREVENT NEPHROPATHIES IN TYPE-2 DIABETIC PATIENTS

    Nov 1, 2019, 00:00

  • PNS207 CANCER-RELATED HEALTH TECHNOLOGY ASSESSMENT (HTA) OUTCOMES BY EUROPEAN HTA AGENCIES: A COMPARATIVE ANALYSIS OF G-BA, HAS AND NICE

    Nov 1, 2019, 00:00

  • PMU31 EARLY COST-EFFECTIVENESS ANALYSIS OF CONTINUOUS MONITORING OF LUNG-AERATION WITH ELECTRICAL IMPEDANCE TOMOGRAPHY IN PRETERM NEONATES WITH RESPIRATORY DISTRESS SYNDROME

    Nov 1, 2019, 00:00

  • PMS25 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF INJURIES TO THE KNEE AND LOWER LEG IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00

  • PGI14 PHARMACOECONOMIC ASPECTS OF TREATMENT OF ACUTE PANCREATIS IN CENTRAL PART OF SERBIA - COST OF ILLNESS STUDY BASED ON DATA FROM TERTIARY REFERRAL HOSPITAL

    Nov 1, 2019, 00:00

  • PDB25 COST-EFFECTIVENESS OF INSULIN DEGLUDEC/ASPART VERSUS BIPHASIC INSULIN ASPART IN PATIENTS WITH TYPE 2 DIABETES IN IRAN

    Nov 1, 2019, 00:00

  • PCN34 CLINICAL AND HUMANISTIC BURDEN AMONG NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS: RESULTS OF A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PMH65 COMPARISON OF CHARACTERISTICS AND MEDICATION-ASSISTED TREATMENT (MAT)-RELATED HEALTHCARE RESOURCE UTILIZATION AMONG US COMMERCIALLY-INSURED PATIENTS WITH OPIOID USE DISORDER (OUD) BY TYPE OF MAT RECEIVED

    Nov 1, 2019, 00:00

  • PND56 BUDGET IMPACT ANALYSIS OF INCLUSION IN THE PUBLIC FINANCING OCRELIZUMAB THERAPY FOR PRIMARY-PROGREDIENT AND HIGHLY ACTIVE REMITTING FORMS OF MULTIPLE SCELEROSIS IN THE RUSSIAN FEDERATION

    Nov 1, 2019, 00:00

  • PCN21 TREATMENT COMPARISONS IN PATIENTS WITH UNRESECTABLE HEPTOCELLULAR CARCINOMA (HCC) WHO ARE INELIGIBLE FOR TRANSARTERIAL CHEMOEMBOLISATION (TACE)

    Nov 1, 2019, 00:00

  • PSS3 INDUCTION COST PER RESPONDER OF BRODALUMAB COMPARED WITH OTHER BIOLOGICS APPROVED FOR PATIENTS WITH MODERATE TO SEVERE PSORIASIS IN CANADA

    Nov 1, 2019, 00:00

  • PNS181 SUBMISSIONS TO A NATIONAL HTA AGENCY IN IRELAND: DRUGS WITH DESIGNATED ORPHAN STATUS

    Nov 1, 2019, 00:00

  • PBI78 CAR-T TREATMENTS: INSIGHTS FROM INITIAL HEALTH TECHNOLOGY ASSESSMENT DECISIONS IN THE UK, GERMANY AND FRANCE

    Nov 1, 2019, 00:00

  • PMS30 SECUKINUMAB VERSUS ADALIMUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: A 52-WEEK COST PER RESPONDER ANALYSIS FROM THE TURKISH PAYER PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCV148 ESTIMATE OF THE IMPACT AND COSTS OF CEREBROVASCULAR DISEASE FROM A HEALTH PLAN IN BRAZIL: REAL WORLD SCENARIO STUDY

    Nov 1, 2019, 00:00

  • NO Specific Disease - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • ND4 WHO BENEFITS MOST FROM COLLABORATIVE DEMENTIA CARE? A POST-HOC SUBGROUP COST-EFFECTIVENESS ANALYSIS

    Nov 1, 2019, 00:00

  • PCN10 A MATCH-ADJUSTED INDIRECT TREATMENT COMPARISON (MAIC) OF LENALIDOMIDE PLUS RITUXIMAB (R2) VERSUS RITUXIMAB PLUS CHEMOTHERAPY (R-CHEMO) FOR RELAPSED AND/OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

    Nov 1, 2019, 00:00

  • PCN74 COST-EFFECTIVENESS OF TREATMENT SEQUENCES FOR BRAF-MUTATED METASTATIC MELANOMA PATIENTS IN REAL LIFE IN FRANCE

    Nov 1, 2019, 00:00

  • PMS27 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF INJURIES TO THE HIP AND THIGH IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00

  • PNS166 WHICH FACTORS INFLUENCE PRICING DECISION WHEN A NEW INDICATION ARRIVES?

    Nov 1, 2019, 00:00

  • PCN457 THE SISAQOL INITIATIVE: ESTABLISHING INTERNATIONAL STANDARDS AND RECOMMENDATIONS FOR THE ANALYSIS OF PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE DATA IN ONCOLOGY RANDOMIZED CLINICAL TRIALS

    Nov 1, 2019, 00:00

  • PNS171 GEOGRAPHICAL INEQUALITIES OF GENERAL PRACTITIONER CARE IN HUNGARY BETWEEN 2009-2016

    Nov 1, 2019, 00:00

  • PNS56 EVALUATION OF THE IMPACT OF ALTERNATIVE DRUG PRICING STRATEGIES USED ON THE BUDGET IMPACT AND COST-EFFECTIVENESS FOR PRODUCTS WITH MULTIPLE INDICATIONS

    Nov 1, 2019, 00:00

  • PCV8 EFFICACY OF VENOUS EXERCISE FOR THE CHANGE OF VENOUS FLOW VELOCITY AMONG PREGNANT WOMEN

    Nov 1, 2019, 00:00

  • PCN88 HOW ARE WE ASSESSING THE VALUE FOR MONEY OF CANCER BIOMARKERS IN ECONOMIC EVALUATIONS?

    Nov 1, 2019, 00:00

  • PMS18 THE EXAMINATION AND DEVELOPMENT OF TRUNK STABILITY IN HIGH SCHOOL STUDENTS

    Nov 1, 2019, 00:00

  • PCN212 ECONOMIC EVALUATION OF TOPOTECAN IN COMPARISON WITH PEGYLATED LIPOSOMAL DOXORUBICIN IN THE TREATMENT OF RECURRENT OVARIAN CANCER IN IRAN

    Nov 1, 2019, 00:00

  • PIH5 USING ARTIFICIAL REPRODUCTIVE DATABASE TO ESTABLISH PREDICTED PROBABILISTIC MODEL OF A SUCCESS LIVE BIRTH AFTER IN VITRO FERTILIZATION

    Nov 1, 2019, 00:00

  • Personalized Precision Medicine - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PCN289 READINESS OF HEALTH SYSTEMS FOR THE INTRODUCTION OF TUMOUR-AGNOSTIC TREATMENT

    Nov 1, 2019, 00:00

  • PNS406 BURDEN OF POST-TRANSPLANT OUTCOMES AFTER LIVER TRANSPLANTATION IN SOUTH KOREA: KOREAN ORGAN TRANSPLANTATION REGISTRY (KOTRY) ANALYSIS STUDY

    Nov 1, 2019, 00:00

  • Sensory System Disorders - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PRO49 ANNUAL COST OF TREATMENT OF SPINAL MUSCULAR ATROPHU PATIENTS IN TURKEY

    Nov 1, 2019, 00:00

  • PUK4 WHERE IS HYPERKALEMIA DIAGNOSED AND DOES IT MATTER? RESULTS FROM A LARGE EMR NETWORK IN THE US

    Nov 1, 2019, 00:00

  • PCN261 ESTIMATING THE NUMBER OF PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE ACROSS EUROPE

    Nov 1, 2019, 00:00

  • PDB77 WILSON'S DISEASE: COST OF HOSPITALIZATION IN GERMANY

    Nov 1, 2019, 00:00

  • PCN230 COST-EFFECTIVENESS ANALYSIS OF PERTUZUMAB WITH TRASTUZUMAB AND CHEMOTHERAPY COMPARED TO TRASTUZUMAB AND CHEMOTHERAPY IN THE NEOADJUVANT TREATMENT OF HER2-POSITIVE EARLY OR LOCALLY ADVANCED BREAST CANCER IN CHINA

    Nov 1, 2019, 00:00

  • PMD7 COMPARING THE LONG-TERM COSTS ASSOCIATED WITH INTRAOCULAR LENS SELECTION AND ND:YAG LASER CAPSULOTOMY POST-CATARACT SURGERY: A COST-CONSEQUENCE ANALYSIS FROM A BELGIAN HEALTHCARE SYSTEM PERSPECTIVE

    Nov 1, 2019, 00:00

  • PMU8 IS PREFERENCE OF ELICITATION TECHNIQUE BASED ON THE DISEASE AREA BEING STUDIED?

    Nov 1, 2019, 00:00

  • PRO83 DATA SOURCES USED TO DETERMINE THE TARGET POPULATION SIZE FOR ORPHAN DRUGS - A REVIEW OF GERMAN AMNOG BENEFIT ASSESSMENTS

    Nov 1, 2019, 00:00

  • Reimbursement Access Policy Research

    Nov 1, 2019, 00:00

  • PRO159 PAEDIATRIC AND ADULT GHD TESTS FOR DIAGNOSIS IN EUROPE

    Nov 1, 2019, 00:00

  • Health Utilities and Costs for Motor Neurone Disease

    Nov 1, 2019, 00:00

  • Drugs Process of Care

    Nov 1, 2019, 00:00

  • PNS196 EXPERIENCES WITH SUPPLEMENTARY HEALTH INSURANCE POLICIES IN HUNGARY AND OTHER EUROPEAN COUNTRIES

    Nov 1, 2019, 00:00

  • PIN7 ANALYSIS OF THE EFFECTIVENESS OF ENHANCE ADHERENCE COUNSELLING (EAC) ON VIRALLY UNSUPPRESSED HIV PATIENTS IN ST CHARLES BORROMEO HOSPITAL, ONITSHA METROPOLIS, ANAMBRA STATE, NIGERIA.

    Nov 1, 2019, 00:00

  • PCN6 EVALUATING THE QUALITY AND RISK OF BIAS IN OVERALL SURVIVAL OUTCOMES FROM NON-RANDOMISED CAR T-CELL THERAPY PIVOTAL TRIALS

    Nov 1, 2019, 00:00

  • PCV13 INCIDENCE AND COST OF BLEEDING EVENTS REQUIRING HOSPITALIZATION IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH ACENOCOUMAROL, IN GREECE

    Nov 1, 2019, 00:00

  • PNS334 SCIENTIFIC MISCONDUCT AND SYSTEMATIC LITERATURE REVIEWS (SLRS): THE IMPACT OF FRAUDULENT CLINICAL STUDIES ON EVIDENCE-BASED MEDICINE

    Nov 1, 2019, 00:00

  • PCN504 REAL-WORLD PROGRESSION-FREE AND OVERALL SURVIVAL OF METASTATIC BREAST CANCER PATIENTS: ANALYSIS OF A NEW GERMAN EMR DATASET

    Nov 1, 2019, 00:00

  • PNS353 PRICING AND MARKET ACCESS LAUNCH EXCELLENCE: WHAT ARE THE KEY CHALLENGES FACING COMPANIES TODAY?

    Nov 1, 2019, 00:00

  • Multiple Diseases - Organizational Practices

    Nov 1, 2019, 00:00

  • PCN396 CHIMERIC ANTIGEN RECEPTOR T-CELLS (CAR-TS): ARE ONGOING CLINICAL TRIALS DESIGNED TO MEET EVIDENCE NEEDS OF KEY EUROPEAN HEALTH TECHNOLOGY ASSESSMENT BODIES (HTABS)?

    Nov 1, 2019, 00:00

  • PSS12 COMPARATIVE ANALYSIS OF GLAUCOMA DRUG CONSUMPTION IN UKRAINE, ESTONIA, AND NORWAY

    Nov 1, 2019, 00:00

  • PIT6 MEASURING PROMS OF REHABILITATION WITH COMPUTER ADAPTIVE TESTING (CAT) AFTER AN OPERATIVE INTERVENTION OF AN EXTREMITY FRACTURE

    Nov 1, 2019, 00:00

  • PDG102 CLINICAL OUTCOMES COMPARING CLOPIDOGREL AND PRASUGREL/ TICAGRELOR IN HONG KONG ACUTE CORONARY SYNDROME POPULATION USING REAL WORLD DATA

    Nov 1, 2019, 00:00

  • Cancer - Economic Evaluation

    Nov 1, 2019, 00:00

  • PDB13 EVALUATING THE ECONOMIC AND HUMANISTIC BURDEN OF TYPE 2 DIABETES MELLITUS IN EMERGING MARKETS COMPARED TO ESTABLISHED MARKETS

    Nov 1, 2019, 00:00

  • PMS8 RATE OF FRACTURES LEADING TO HOSPITALISATION AND HEALTHCARE BURDEN IN UNTREATED OSTEOPOROSIS ELDERLY PATIENTS IN GERMANY: AN INGEF HEALTHCARE INSURANCE DATABASE ANALYSIS

    Nov 1, 2019, 00:00

  • Sensory System Disorders - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PNS351 ROLE OF MARKET ACCESS (MA), AND HEALTH ECONOMIC AND OUTCOMES RESEARCH (HEOR) PROFESSIONALS IN THE UPTAKE OF PHARMACEUTICAL PRODUCTS.

    Nov 1, 2019, 00:00

  • PNS66 NON-INFERIORITY TRIALS IN HEALTH TECHNOLOGY ASSESSMENT - DO THEY NECESSITATE A COST-MINIMISATION APPROACH?

    Nov 1, 2019, 00:00

  • Musculoskeletal Disorders - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PDB58 A LITERATRUE REVIEW OF THE ECONOMIC BURDEN OF HYPOGLYCEMIA IN PATIENTS WITH DIABETES MELLITUS IN CHINA

    Nov 1, 2019, 00:00

  • PNS322 REVIEW OF METHODOLOGICAL APPROACHES TO ANALYSE LONGITUDINAL UTILITY DATA

    Nov 1, 2019, 00:00

  • PBI34 BUDGET IMPACT OF TRASTUZUMAB BIOSIMILARS FOR THE TREATMENT OF BREAST CANCER AND GASTRIC CANCER IN GREECE

    Nov 1, 2019, 00:00

  • PRO42 THE CLINICAL, HUMANISTIC AND ECONOMIC BURDEN OF BRONCHIOLITIS OBLITERANS SYNDROME IN EUROPE

    Nov 1, 2019, 00:00

  • PIN134 USING TIME-DEPENDENT PROPENSITY SCORE MATCHING TO ACCOUNT FOR PATIENT’S CHANGING CLINICAL STATUS LEADING UP TO THE THERAPEUTIC INTERVENTION: AN EXAMPLE USING REAL-WORLD DATA

    Nov 1, 2019, 00:00

  • PCV64 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF CARDIAC ARREST IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00

  • Multiple Diseases - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PAM13 IMPACT ON CARERS OF ADULT PATIENTS RECEIVING PARENTERAL SUPPORT FOR SHORT BOWEL SYNDROME-ASSOCIATED INTESTINAL FAILURE

    Nov 1, 2019, 00:00

  • PND32 COST-EFECTIVENESS AND BUDGET IMPACT OF VAGUS NERVE STIMULATION WITH ASPIRE SR MODEL 106 COMPARED TO ANTI-EPILEPTIC DRUGS IN A SUBGROUP OF PATIENTS WITH DRUG RESISTANT EPILEPSY IN PUBLIC SETTING IN TURKEY

    Nov 1, 2019, 00:00

  • PCN447 NEW METHODOLOGY IN PARAMETRIC NETWORK META-ANALYSIS: NON-MIXTURE CURE MODELS

    Nov 1, 2019, 00:00

  • PDG53 A FOCUS GROUP STUDY TO IDENTIFY THE FACTORS INFLUENCING PRIORITY SETTING IN HEALTHCARE: FOCUSING ON AGE AND SEVERITY

    Nov 1, 2019, 00:00

  • PBI42 ANALYSIS OF GENE AND CELL THERAPIES POLICIES IN EUROPEAN COUNTRIES

    Nov 1, 2019, 00:00

  • PCN450 FITTING A MIXTURE MODEL OF CANCER EXCESS MORTALITY RATES WITH A TRANSFORMATION STEP, TO CANCER RELATIVE SURVIVAL DATA.

    Nov 1, 2019, 00:00

  • PND28 THE ECONOMIC BURDEN OF MULTIPLE SCLEROSIS DEVELOPMENT OVER TIME: AN ANALYSIS FROM THE MULTIPLE SCLEROSIS CENTERS PERSPECTIVE

    Nov 1, 2019, 00:00

  • PSU20 APPLY PRINCIPLES AND GOOD PRACTICE OF BUDGET IMPACT ANALYSIS IN MODEL FRAMEWORK DEVELOPMENT FOR SURGICAL DEVICE

    Nov 1, 2019, 00:00

  • PSS19 HEALTH-RELATED QUALITY OF LIFE, WORK PRODUCTIVITY, AND ASSOCIATED FINANCIAL BURDEN AMONG ADULTS WITH PSORIASIS

    Nov 1, 2019, 00:00

  • PCN272 OBINUTUZUMAB TREATMENT ON 1ST LINE HIGH AND INTERMEDIATE RISK FOLLICULAR LYMPHOMA. SHORT-TERM REDUCTION OF RELAPSED OR REFRACTORY DIRECT MEDICAL COSTS IN ARGENTINA AND CHILE.

    Nov 1, 2019, 00:00

  • PCN529 BURDEN OF ILLNESS IN NEW OSTOMATES: AN ANALYSIS BASED ON GERMAN CLAIMS DATA

    Nov 1, 2019, 00:00

  • PRO48 COST OF HAEMATOPOIETIC STEM CELL TRANSPLANT IN TURKEY

    Nov 1, 2019, 00:00

  • PMU55 HURDLES TO REGULATORY AND ACCESS (PRICING AND REIMBURSEMENT) OF 3D-PRINTED TUMOR ASSAYS FOR PERSONALIZED MEDICINE IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PND126 ANTI-DEMENTIA DRUGS: CHANGING PRESCRIBING PATTERNS WITH THE INTRODUCTION OF GENERIC DRUGS

    Nov 1, 2019, 00:00

  • PCN359 VALUE ASSESSMENT OF HTA DECISIONS FOR PD-1/PD-L1 INHIBITORS IN ONCOLOGY: A NICE PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCN3 RITUXIMAB-BASED REGIMEN AS FRONTLINE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-WORLD NATIONWIDE COHORT STUDY

    Nov 1, 2019, 00:00

  • PDB23 SWITCHING TO INSULIN DEGLUDEC IS A COST-SAVING THERAPY FOR PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES IN THE SWEDISH SETTING BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00

  • PGI13 COST PER RESPONDER ANALYSIS EVALUATED THROUGH CLINICAL RESPONSE AND REMISSION RATE OF ADALIMUMAB, USTEKINUMAB AND VEDOLIZUMAB FOR THE TREATMENT OF CROHN'S DISEASE FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCN428 SCALABLE PREDICTION OF CANCER PATIENT CLINICAL EVENTS IN REAL WORLD CLINICAL SETTINGS

    Nov 1, 2019, 00:00

  • PDB42 COST-EFFECTIVENESS ANALYSIS FOR HBA1C TEST INTERVALS IN PATIENTS ON TREATMENT FOR STABLE TYPE 2 DIABETES

    Nov 1, 2019, 00:00

  • PCN172 COST-EFFECTIVENESS OF CRC FRENCH SCREENING PROGRAMME FOR AVERAGE RISK INDIVIDUALS

    Nov 1, 2019, 00:00

  • PNS124 FRAMEWORK CONCEPTS FOR FINANCIAL RISK SHARING IN NOVEL POTENTIALLY CURATIVE MODALITIES

    Nov 1, 2019, 00:00

  • PMU80 DETERMINING THE EPIDEMIOLOGY, PATIENT FLOW, TREATMENT AND UNMET NEEDS OF PATIENTS WITH CHRONIC LIVER DISEASE-ASSOCIATED SEVERE THROMBOCYTOPENIA UNDERGOING INVASIVE PROCEDURES IN SPAIN

    Nov 1, 2019, 00:00

  • PCV80 EVALUATION OF THE QUALITY OF LIFE OF PATIENTS WITH CARDIOVASCULAR DISEASES IN NUR-SULTAN, KAZAKHSTAN

    Nov 1, 2019, 00:00

  • PNS222 NEEDS AND RISKS ASSESSMENT IN CREATION OF HTA-INFORMED HEALTH CARE DECISION-MAKING ECOSYSTEM IN UKRAINE

    Nov 1, 2019, 00:00

  • PSY35 A COMPARATIVE ANALYSIS OF HEALTH TECHNOLOGY ASSESSMENTS EVALUATING RECENTLY APPROVED BIOLOGICAL THERAPIES FOR ADULT PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS IN THE US, CANADA AND UK

    Nov 1, 2019, 00:00

  • PCV63 WHAT'S THE COST OF HOSPITALISATIONS DUE TO HEART FAILURE WITH PRESERVED EJECTION FRACTION IN THE UNITED STATES?

    Nov 1, 2019, 00:00

  • PND38 10-YEAR COST-EFFECTIVENESS ANALYSES OF FREMANEZUMAB COMPARED TO ERENUMAB AS PREVENTIVE TREATMENT IN EPISODIC MIGRAINE FOR PATIENTS WITH INADEQUATE RESPONSE TO PRIOR PREVENTIVE TREATMENTS

    Nov 1, 2019, 00:00

  • PMS70 PSYCHOLOGICAL SYMPTOMS AND TOTAL KNEE REPLACEMENT.

    Nov 1, 2019, 00:00

  • PND87 SYSTEMATIC LITERATURE REVIEW OF HEALTH STATE UTILITY VALUES (HSUVS) IN MULTIPLE SCLEROSIS

    Nov 1, 2019, 00:00

  • PDB108 THE UNMET MEDICAL NEEDS IN CURRENT ANTIDIABETIC INJECTABLE THERAPY (AIT) IN CHINA: FROM THE PERSPECTIVE OF HEALTHCARE PROVIDERS (HCPS)

    Nov 1, 2019, 00:00

  • PNS327 DO FLEXIBLE SURVIVAL MODELS PROVIDE BETTER EXTRAPOLATIONS THAN STANDARD SURVIVAL MODELS? A SIMULATION STUDY

    Nov 1, 2019, 00:00

  • PNS315 ON THE USE OF DISCOUNT RATES IN ONE-WAY SENSITIVITY ANALYSIS

    Nov 1, 2019, 00:00

  • PDB91 AN MCDA APPROACH IN THE EVALUATION OF NEW TECHNOLOGIES FOR FAMILIAL HYPERCHOLESTEROLEMIA TREATMENT

    Nov 1, 2019, 00:00

  • PIN34 A PUBLIC HEALTH AND BUDGET IMPACT ANALYSIS (BIA) OF VACCINATING CHILDREN AGAINST PNEUMOCOCCAL-DISEASES IN AUSTRIA

    Nov 1, 2019, 00:00

  • PAM14 ASSESSING THE NUTRITIONAL STATUS OF THE ELDERLY USING STANDARD STATUS SCALES

    Nov 1, 2019, 00:00

  • PDB73 RELATIONSHIP BETWEEN METABOLIC SYNDROME RISK LEVEL, BODY COMPOSITION AND LIPID PROFILE AMONG ADULTS IN MONGOLIA

    Nov 1, 2019, 00:00

  • NO Specific Disease - Organizational Practices

    Nov 1, 2019, 00:00

  • PNS42 TO WHAT EXTENT DOES SEEKING CLINICAL EXPERT OPINION FOR MODEL INPUTS REDUCE THE COST OF UNCERTAINTY? A CONCEPTUAL APPROACH USING EXPECTED VALUE OF PERFECT PARAMETER INFORMATION (EVPPI)

    Nov 1, 2019, 00:00

  • PMU132 PUBLICATION PATTERNS IN PATIENT-REPORTED OUTCOMES IN ORIGINAL RESEARCH ARTICLES ABOUT DIABETES AND INFLAMMATORY BOWEL DISEASE

    Nov 1, 2019, 00:00

  • PCN76 A COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB FOR PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN PORTUGAL

    Nov 1, 2019, 00:00

  • NO Specific Disease - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PMS41 PROJECTION OF THE PREVALENCE OF RHEUMATIC DISEASES IN PORTUGAL THROUGH THE FIRST HALF OF THE 21ST CENTURY

    Nov 1, 2019, 00:00

  • PRO50 THE ECONOMIC BURDEN OF SHORT-TERM ADVERSE EVENTS ASSOCIATED WITH THE CHOP CHEMOTHERAPY REGIMEN IN PATIENTS WITH LYMPHOPROLIFERATIVE DISORDERS IN EUROPEAN COUNTRIES: A COMPREHENSIVE LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PMU51 BARRIERS AGAINST PROGRAMS FOR THE PREVENTION OF IODINE DEFICIENCY DISORDERS IN EUROPE: A DELPHI STUDY

    Nov 1, 2019, 00:00

  • PIH17 COST-EFFECTIVENESS OF INTERVENTIONS PREVENTING FALLS IN OLDER ADULTS: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PBI68 ADDED BENEFIT ASSESSMENT OF ATMPS IN GERMANY: DOES THE DATA BASIS MEET HTA REQUIREMENTS?

    Nov 1, 2019, 00:00

  • PRO109 A COMPARATIVE REVIEW OF NICE AND SMC DECISION-MAKING FOR ULTRA-ORPHAN MEDICINES

    Nov 1, 2019, 00:00

  • PCV136 PATIENT PREFERENCES FOR MITRAL VALVE PROCEDURE-ASSOCIATED BENEFITS REVEAL GREATER RISK TOLERANCE AS HEART FAILURE SYMPTOMS WORSEN

    Nov 1, 2019, 00:00

  • PRO24 COST-EFFECTIVENESS ANALYSIS OF PROPHYLAXIS VS. ON-DEMAND TREATMENT FOR HAEMOPHILIA B CHILDREN WITHOUT INHIBITOR IN CHINA

    Nov 1, 2019, 00:00

  • PIH44 SURGICAL TREATMENT OF PATIENTS NEWLY DIAGNOSED WITH UTERINE FIBROIDS: A CLAIMS-BASED DATA ANALYSIS

    Nov 1, 2019, 00:00

  • PNS298 PER-MEMBER PER-MONTH (PMPM) EXPENDITURE VALUE IN ONCOLOGY: A QUICK LITERATURE REVIEW AND OPINION

    Nov 1, 2019, 00:00

  • ON4 THE ECONOMIC BURDEN OF RENAL CELL CARCINOMA (RCC) IN CANADA USING REAL-WORLD EVIDENCE; A SOCIETAL PERSPECTIVE.

    Nov 1, 2019, 00:00

  • PCN89 COST-EFFECTIVENESS OF NIVOLUMAB AS ADJUVANT TREATMENT OF MELANOMA IN ADULTS WITH INVOLVEMENT OF LYMPH NODES OR METASTATIC DISEASE WHO HAVE UNDERGONE COMPLETE RESECTION IN BELGIUM

    Nov 1, 2019, 00:00

  • PIN116 THE BURDEN OF INFLUENZA POSITIVE INPATIENTS IN TURKEY

    Nov 1, 2019, 00:00

  • PCN435 IMPROVED ESTIMATES OF EXTRAPOLATED MEAN SURVIVAL TIMES USING FINITE MIXTURE MODELS: REDUCING UNCERTAINTY IN COST EFFECTIVENESS ANALYSIS

    Nov 1, 2019, 00:00

  • PCN23 UPDATED NETWORK META-ANALYSIS OF TREATMENTS IN FIRST-LINE ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA

    Nov 1, 2019, 00:00

  • PNS23 THE IMPACT OF EARLY CENSORING ON THE PFS BY A MULTI-STATE MODEL

    Nov 1, 2019, 00:00

  • PMU144 DISEASE STATE ADAPTATION AND ESTIMATES OF QUALITY-OF-LIFE: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PIH65 IMPACT ON CARERS OF PAEDIATRIC PATIENTS RECEIVING PARENTERAL SUPPORT FOR SHORT BOWEL SYNDROME-ASSOCIATED INTESTINAL FAILURE

    Nov 1, 2019, 00:00

  • PSY5 COST-UTILITY OF TOFACITINIB FOR THE TREATMENT OF SEVERE TO MODERATE RHEUMATOID ARTHRITIS IN PORTUGAL

    Nov 1, 2019, 00:00

  • PCN273 EPIDEMIOLOGY AND UNMET NEEDS OF BLADDER CANCER IN ITALY

    Nov 1, 2019, 00:00

  • PGI59 INCREASED AVAILABILITY OF REIMBURSED INTERFERON-FREE TREATMENTS FOR HCV IN POLAND AND ITS COST

    Nov 1, 2019, 00:00

  • PIH67 THE CHANGES OF COST FOR PREECLAMPSIA PREGNANCY AFTER THE ANGIOGENIC FACTORS (SFLT-1 AND PLGF) TESTS. PRELIMINARY DATA OF AN ECONOMIC MODEL BASED ON LOCAL RWD.

    Nov 1, 2019, 00:00

  • PNS356 PAYERS RELATED ISSUES ARISING FROM THE DEVELOPMENT OF PHARMACEUTICAL PRODUCTS AT PRE-LAUNCH

    Nov 1, 2019, 00:00

  • PRO114 EQ-5D UTILITY ESTIMATES FOR PATIENTS WITH SYSTEMIC SCLEROSIS (SSC). INSIGHTS FROM THE FOCUSSCED PHASE III EFFICAY AND SAFETY STUDY OF TOCILIZUMAB.

    Nov 1, 2019, 00:00

  • PCV129 SELF-ASSESSED FUNCTIONAL INSTRUMENT IN HEART FAILURE: CORRELATION WITH PATIENT REPORTED SYMPTOMS

    Nov 1, 2019, 00:00

  • PNS157 WHY EMERGENCY ACCESS TO DRUG TECHNOLOGES IN POLAND DOES NOT WORK?

    Nov 1, 2019, 00:00

  • PCV143 SACUBITRIL/VALSARTAN PRESCRIPTION PATTERNS AND TITRATION IN A REAL-WORLD SETTING IN PORTUGAL: AN ANALYSIS OF THE PRIME STUDY

    Nov 1, 2019, 00:00

  • PND82 A DELPHI PANEL ON TREATMENT OF HIGH DISEASE ACTIVITY RELAPSING REMITTING MULTIPLE SCLEROSIS IN THE NETHERLANDS

    Nov 1, 2019, 00:00

  • PCV29 COST-EFFECTIVENESS OF CORONARY AND PERIPHERAL ARTERY DISEASE TREATMENTS

    Nov 1, 2019, 00:00

  • PCN12 USING CLINICAL DATA STANDARDS TO FACILITATE COMPARISONS OF ACUTE MYELOID LEUKEMIA TREATMENT PATTERNS AND OUTCOMES IN REAL WORLD CLINICAL CARE AND POOLED CLINICAL TRIAL POPULATIONS

    Nov 1, 2019, 00:00

  • PDG68 USE OF ANTICANCER DRUGS IN IVORY COAST FROM 2017 TO 2018

    Nov 1, 2019, 00:00

  • PNS80 COST-EFFECTIVENESS ANALYSES OF PERSONALISATION/HOME CARE FOR OLDER PEOPLE COMPARED TO NURSING HOME CARE: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PNS331 QUANTIFYING THE ACCEPTABILITY OF HEALTH PROBLEMS IN DIFFERENT AGES USING THE EQ-5D-3L INSTRUMENT

    Nov 1, 2019, 00:00

  • PBI41 CHALLENGES AND OPPORTUNITIES FOR THE REIMBURSEMENT OF GENE THERAPIES - STAKEHOLDER INSIGHTS FROM GERMANY, SWEDEN AND THE UNITED KINGDOM

    Nov 1, 2019, 00:00

  • PND71 EPIDEMIOLOGY OF ATTENTION DEFICIT HYPERACTIVITY DISORDERS IN SPAIN BASED ON REAL-WORLD DATA

    Nov 1, 2019, 00:00

  • PNS36 A CONCEPTUAL PAPER ON THE USE OF PATIENT SUPPORT PROGRAMS IN PROVIDING BETTER ACCESS TO MEDICAL CARE IN EGYPT

    Nov 1, 2019, 00:00

  • PNS45 ADDING NOISE TO MARKOV COHORT MODELS

    Nov 1, 2019, 00:00

  • PRO150 A SYSTEMATIC LITERATURE REVIEW OF HEALTH STATE UTILITY VALUATIONS IN HAEMOPHILIA

    Nov 1, 2019, 00:00

  • PRO75 PATIENT ACCESS TO ORPHAN MEDICINES IN TURKEY

    Nov 1, 2019, 00:00

  • PDB50 DOES THE APPLICATION OF UKPDS RISK EQUATIONS UNDERESTIMATE THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN TYPE 2 DIABETES MELLITUS?

    Nov 1, 2019, 00:00

  • PRO5 COMPARING PRODUCTIVITY LOSSES FROM TREATING ATYPICAL HEMOLYTIC UREMIC SYNDROME PATIENTS IN THE UNITED STATES WITH ECULIZUMAB OR RAVULIZUMAB IN AN INFUSION CLINIC OR AT HOME

    Nov 1, 2019, 00:00

  • PIN73 THE POTENTIAL COST-EFFECTIVENESS OF QUADRIVALENT VERSUS TRIVALENT INACTIVATED INFLUENZA VACCINE FOR THE PORTUGUESE ELDERLY POPULATION

    Nov 1, 2019, 00:00

  • PMD26 THE ECONOMIC EVALUATION OF THE SFLT-1/PIGF RATIO IN THE PREDICTION OF PRE-ECLAMPSIA

    Nov 1, 2019, 00:00

  • PMU104 NAVIGATING DIVERGENCE: ACCOMMODATING THE MULTITUDE OF NEW PAYER BODIES IN EMERGING MARKETS

    Nov 1, 2019, 00:00

  • PCN217 COST-EFFECTIVENESS OF LENVATINIB IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN THE UK

    Nov 1, 2019, 00:00

  • PNS337 IMPROVING ON CYCLE CORRECTIONS FOR TIME-HOMOGENEOUS MARKOV MODELS

    Nov 1, 2019, 00:00

  • PNS227 THE NOT-NICE ACCESS PATHWAY: NHS ENGLAND SPECIALISED COMMISSIONING

    Nov 1, 2019, 00:00

  • PBI21 TREATMENT COSTS OF MATRIX-ASSOCIATED AUTOLOGOUS CHONDROCYTES IMPLANTATION COMPARED TO MICROFRACTURE — RESULTS OF A MATCHED-PAIR CLAIMS DATA ANALYSIS ON TREATMENT OF CARTILAGE KNEE DEFECTS IN GERMANY

    Nov 1, 2019, 00:00

  • PSU14 HEALTHCARE BURDEN OF SURGICAL SITE INFECTIONS FOLLOWING CORONARY ARTERY BYPASS GRAFT SURGERY

    Nov 1, 2019, 00:00

  • PRO22 HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND ECONOMIC BURDEN OF DUCHENNE MUSCULAR DYSTROPHY (DMD): A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PND116 QUALITATIVE CONCEPT ELICITATION INTERVIEWS TO UNDERSTAND THE PATIENT EXPERIENCE OF GLUCOCEREBROSIDASE-PARKINSON'S DISEASE (GBA-PD)

    Nov 1, 2019, 00:00

  • AI2 GEO-SPATIAL RISK ASSESSMENT OF ASTHMA HEALTH RESOURCE USE AT THE MUNICIPAL LEVEL IN THE GREATER HELSINKI METROPOLITAN AREA OF FINLAND

    Nov 1, 2019, 00:00

  • PRS68 A RETROSPECTIVE DATABASE STUDY OF A CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION PATIENT COHORT TO EVALUATE THE PATIENT CHARACTERISTICS AND ECONOMIC BURDEN OF ILLNESS IN ENGLAND

    Nov 1, 2019, 00:00

  • PCN77 COST-UTILITY, COST-EFFECTIVENESS, AND BUDGET IMPACT OF INTERNET-BASED COGNITIVE BEHAVIOURAL THERAPY FOR BREAST CANCER SURVIVORS WITH TREATMENT-INDUCED MENOPAUSAL SYMPTOMS

    Nov 1, 2019, 00:00

  • PDB24 REAL WORLD DATA ANALYSIS OF HEALTHCARE RESOURCE USE OF PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE

    Nov 1, 2019, 00:00

  • PCN30 ROLE OF CAR-T CELLS THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

    Nov 1, 2019, 00:00

  • PUK16 COST-UTILITY ANALYSIS OF MIRABEGRON VERSUS ANTIMUSCARINIC THERAPY IN THE TREATMENT OF OVERACTIVE BLADDER

    Nov 1, 2019, 00:00

  • PMH36 ST. JOHN'S WORT THERAPY IS ASSOCIATED WITH A REDUCED INCIDENCE OF DEMENTIA IN PATIENTS TREATED IN GENERAL PRACTICES

    Nov 1, 2019, 00:00

  • PMU54 A 10-YEAR REVIEW (2009-2018) OF MARKET ACCESS OF PHARMACEUTICALS IN THE EU5 AND US

    Nov 1, 2019, 00:00

  • PNS129 NET PRICES OF GENERICS IN GREECE DUE TO PAYBACKS: UPDATING THE FACTS

    Nov 1, 2019, 00:00

  • PIH62 INVESTIGATING THE RESPONSIVENESS TO CHANGE OF THE HIV TREATMENT SATISFACTION QUESTIONNAIRE CHANGE VERSION (HIVTSQC) IN OVERCOMING CEILING EFFECTS IN THE HIV TREATMENT SATISFACTION QUESTIONNAIRE STATUS VERSION (HIVTSQS)

    Nov 1, 2019, 00:00

  • PNS382 ACCURACY OF PRO DATA SIGNIFICANTLY IMPROVES WITH SUBJECT TRAINING IN MIGRAINE CLINICAL TRIALS

    Nov 1, 2019, 00:00

  • Urinary/Kidney Disorders - Health Technology Assessment

    Nov 1, 2019, 00:00

  • Personalized Statistical Research

    Nov 1, 2019, 00:00

  • PNS64 DOES IT WORTH TO INVEST ON INTRAOPERATIVE HYPOTHERMIA PREVENTION? - HYBRID EVIDENCES FROM META-ANALYSES AND COST-BENEFIT ANALYSIS

    Nov 1, 2019, 00:00

  • Multiple Diseases - Medical Technologies

    Nov 1, 2019, 00:00

  • PCN169 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC RENAL CELL CARCINOMA IN GREECE

    Nov 1, 2019, 00:00

  • Multiple Diseases - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PBI66 ARE HTA AGENCIES BUYING INTO THE CAR-T HYPE?

    Nov 1, 2019, 00:00

  • PNS62 HEALTH ECONOMIC VALUE OF BLOOD IN GHANA: THE CASE OF MATERNAL BLEEDING

    Nov 1, 2019, 00:00

  • PND30 THE SOCIETAL IMPACT OF ERENUMAB IN PROPHYLACTIC TREATMENT OF PATIENTS WITH MIGRAINE IN GERMANY: A MACROECONOMIC OPEN-COHORT APPROACH

    Nov 1, 2019, 00:00

  • PBI49 THE EXPEDITED REGULATORY PROGRAMS FOR REGENERATIVE MEDICINES IN US, EU AND JAPAN

    Nov 1, 2019, 00:00

  • PMU151 ECONOMIC BURDEN OF BIOSIMILAR DELIVERY IN FRANCE: REAL WORLD ANALYSIS FROM THE PERMANENT SAMPLE OF NATIONAL HEALTH INSURANCE BENEFICIARIES, BETWEEN 2007 TO 2017

    Nov 1, 2019, 00:00

  • PMD16 HEALTH ECONOMIC VALUE OF BLOOD IN IVORY COAST: THE CASE OF MATERNAL BLEEDING

    Nov 1, 2019, 00:00

  • PCN220 COST-EFFECTIVENESS ANALYSIS OF ALECTINIB VERSUS CRIZOTINIB IN FIRST LINE ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCN210 RESOURCE UTILIZATION AND COST FOR WOMEN WITH ADVANCED HR+/HER2- BREAST CANCER IN COLOMBIAN HEALTH CARE SETTINGS

    Nov 1, 2019, 00:00

  • PCN433 DISCRETE TIME RESTRICTED CUBIC SPLINE MODELS FOR NETWORK META-ANALYSIS OF TIME-TO-EVENT OUTCOMES

    Nov 1, 2019, 00:00

  • PCN189 COST-EFFECTIVENESS ANALYSIS OF PALBOCICLIB PLUS FULVESTRANT VERSUS EVEROLIMUS PLUS EXEMESTAN IN THE TREATMENT OF ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE, ADVANCED BREAST CANCER IN IRAN

    Nov 1, 2019, 00:00

  • PCN381 KEY FACTORS FOR THE CONSIDERATION OF QUALITY OF LIFE DATA IN AMNOG BENEFIT ASSESSMENTS

    Nov 1, 2019, 00:00

  • PMD45 A COMPANION APP TO SUPPORT PATIENTS TREATED WITH CERTOLIZUMAB PEGOL: RESULTS FROM A USABILITY STUDY

    Nov 1, 2019, 00:00

  • PND37 10-YEAR COST-EFFECTIVENESS ANALYSES OF RESPONSE-BASED USE OF FREMANEZUMAB AS PREVENTIVE TREATMENT IN CHRONIC AND EPISODIC MIGRAINE FOR PATIENTS WITH INADEQUATE RESPONSE TO PRIOR PREVENTIVE TREATMENTS

    Nov 1, 2019, 00:00

  • PCN152 COST-UTILITY AUC MODEL ADAPTED TO ITALIAN CLINICAL PRACTICE FOR EVALUATION OF ENTRECTINIB VERSUS STANDARD OF CARE IN ROS1+ NSCLC PATIENTS

    Nov 1, 2019, 00:00

  • PNS136 MEDICAL DEVICES PRICE SETTING IN FRANCE: A RETROSPECTIVE ANALYSIS (2018-2019)

    Nov 1, 2019, 00:00

  • PRS52 DEVELOPMENT OF A NOVEL ECONOMIC MODELING APPROACH FOR ASTHMA

    Nov 1, 2019, 00:00

  • PDB11 HIPOS-WARD (HYPOGLICEMIA IN PORTUGAL OBSERVATIONAL STUDY - WARD PATIENTS): TOTAL COSTS

    Nov 1, 2019, 00:00

  • PIN75 WHAT WE KNOW NOW: REVISITING THE COST-EFFECTIVENESS OF CHICKENPOX VACCINATION USING AN AGENT-BASED MODEL

    Nov 1, 2019, 00:00

  • CE3 COMPARATIVE EFFECTIVENESS AMONG SINGLE AGENT CHEMOTHERAPEUTICS IN THE TREATMENT OF TNBC USING TIME TO NEXT TREATMENT AS A SURROGATE FOR EFFICACY

    Nov 1, 2019, 00:00

  • PDB71 ASSOCIATION OF SEVERE HYPOGLYCEMIA WITH ALL-CAUSE MORTALITY AND COMPLICATIONS AMONG PATIENTS WITH DIABETES MELLITUS IN CHINA

    Nov 1, 2019, 00:00

  • PDG48 AN ANALYSIS OF THE DANISH MODEL FOR ANALOGUE COMPETITION OF HOSPITAL MEDICINE BASED ON THE THERAPEUTIC AREA, HEPATITIS C

    Nov 1, 2019, 00:00

  • CV4 HOSPITALIZED WITH STROKE AT THE WEEKEND: ARE THERE HIGHER RISK OF EARLY DEATH AND HIGHER COSTS?

    Nov 1, 2019, 00:00

  • PCN136 ECONOMIC VIABILITY OF CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR ADULTS WITH ADVANCED LEUKEMIA: EVIDENCE FROM AN EARLY ECONOMIC MODELLING

    Nov 1, 2019, 00:00

  • PCN111 COMPARISON OF ADVERSE EVENT COSTS OF NIVOLUMAB+IPILIMUMAB VERSUS SUNITINIB FOR PREVIOUSLY UNTREATED INTERMEDIATE-/POOR-RISK ADVANCED RENAL CELL CARCINOMA IN SWITZERLAND

    Nov 1, 2019, 00:00

  • PDG83 PHARMACEUTICAL PRICING: LAUNCH STRATEGY RULES? ANALYSIS OF GERMAN DATA

    Nov 1, 2019, 00:00

  • PNS75 PROPER INCORPORATION OF ADVERSE EVENTS FROM MEDICAL TREATMENTS (AEMT) IN HEALTH TECHOLOGY ASSESSMENTS (HTA)

    Nov 1, 2019, 00:00

  • PIH35 RATES OF DELIVERY WITH COMPLICATING CONDITIONS AND POSTPARTUM COMPLICATION RATES FOLLOWING DELIVERY SURGE AMONG U.S. MOTHERS

    Nov 1, 2019, 00:00

  • Surgery - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PRS20 INFLUENCE OF COPD SEVERITY AND ITS COMORBIDITIES ON DIRECT AND INDIRECT COSTS: RESULTS FROM THE LQ-DMP STUDY

    Nov 1, 2019, 00:00

  • PRO149 PATIENT ENGAGEMENT IN RESEARCH: THE EURORDIS PATIENT-LED COMMUNITY ADVISORY BOARDS (CABS)

    Nov 1, 2019, 00:00

  • PGI29 AN ECONOMIC EVALUATION OF TOFACITINIB IN THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE UNITED KINGDOM

    Nov 1, 2019, 00:00

  • PCN72 COMPARATIVE COST ANALYSIS OF SUBCUTANEOUS TRASTUZUMAB ORIGINATOR (HERCEPTIN®) VS INTRAVENOUS TRASTUZUMAB BIOSIMILAR (KANJINTI) FROM A HOSPITAL PERSPECTIVE IN ITALY

    Nov 1, 2019, 00:00

  • PMD9 INTRODUCING BUDGET IMPACT ANALYSIS COMPARING REUSABLE TO SINGLE-USE BRONCHOSCOPES WITHIN A LARGE UK UNIVERSITY HOSPITAL

    Nov 1, 2019, 00:00

  • PCV71 INDIRECT COMPARISON OF NEUROPROTECTORS IN THE TREATMENT OF ISCHEMIC STROKE IN THE RUSSIAN FEDERATION

    Nov 1, 2019, 00:00

  • PCN432 EVALUATION OF MISSING DATA IMPUTATION STRATEGIES IN CLINICAL TRIAL AND EMR DATA USING STANDARDIZED DATA MODELS

    Nov 1, 2019, 00:00

  • RARE Orphan Diseases - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PRO53 WHAT IS THE RELATIONSHIP BETWEEN PRICE AND PREVALENCE IN NON-ONCOLOGY RARE DISEASE?

    Nov 1, 2019, 00:00

  • PMS29 HEALTH STATE UTILITY VALUES FOR JUVENILE IDIOPATHIC ARTHRITIS: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PIH34 THE ASSOCIATION BETWEEN ANTICHOLINERGIC MEDICINE AND COGNITION DECLINE IN OLDER ADULTS: A SYSTEMIC REVIEW AND META-ANALYSIS

    Nov 1, 2019, 00:00

  • PCV114 FEASIBILITY OF USING REAL WORLD EVIDENCE TO INFORM DECISIONS ON CONDUCTING A COST EFFECTIVENESS ANALYSIS: AN EXAMPLE OF STROKE RISK REDUCTION THERAPIES IN ATRIAL FIBRILLATION

    Nov 1, 2019, 00:00

  • PRO154 CONFIRMATORY PSYCHOMETRIC VALIDATION OF THE BRIEF PAIN INVENTORY (BPI-SF) IN ADULT X-LINKED HYPOPHOSPHATEMIA (XLH)

    Nov 1, 2019, 00:00

  • PMU77 OPIOID USE PATTERNS AND HEALTHCARE USE AMONG INDIVIDUALS WITH COMORBID CHRONIC NON-CANCER PAIN AND OBSTRUCTIVE SLEEP APNEA

    Nov 1, 2019, 00:00

  • PSY8 ECONOMIC EVALUATION OF GUSELKUMAB AND OTHER IL-INHIBITORS FOR THE TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN ITALY

    Nov 1, 2019, 00:00

  • PNS307 THE COMBINED USE OF TREEAGE SOFTWARE TO ACCELERATE MARKOV MODEL CONSTRUCTION WITHIN AN EXCEL USER INTERFACE

    Nov 1, 2019, 00:00

  • PCN84 COST OF ILLNESS OF CUTANEOUS SQUAMOUS CELL CARCINOMA IN ITALY

    Nov 1, 2019, 00:00

  • PCN515 A SURVEY OF CLINICAL PRACTICE FOR THE FRONTLINE TREATMENT OF PERIPHERAL T-CELL LYMPHOMA (PTCL) IN THE UNITED KINGDOM

    Nov 1, 2019, 00:00

  • PNS247 THE IMPLICATIONS OF EUROPEAN JOINT CLINICAL ASSESSMENT FOR MEMBER STATE PRICING MARKET ACCESS

    Nov 1, 2019, 00:00

  • PRO148 PSYCHOMETRIC EVALUATION OF A MODIFIED VISUAL FUNCTION QUESTIONNAIRE (MVFQ-25) USING DATA FROM A PHASE III OPEN-LABEL RANDOMIZED CONTROLLED TRIAL IN PATIENTS WITH INHERITED RETINAL DYSTROPHY CAUSED BY BIALLELIC RPE65 MUTATIONS

    Nov 1, 2019, 00:00

  • PSS23 DISEASE BURDEN IN PATIENTS WITH MILD PSORIASIS: GROUP CONCEPT MAPPING

    Nov 1, 2019, 00:00

  • PND83 ACCESS TO INTRAVENOUS TISSUE-LIKE PLASMINOGEN ACTIVATOR (IV TPA) THERAPY AND MECHANICAL THROMBECTOMY (MT) FOR PATIENTS WITH ACUTE ISCHEMIC STROKE IN HUNGARY

    Nov 1, 2019, 00:00

  • PNS101 ASSOCIATION BETWEEN RISK FACTORS AND SAFE DRUG DISPOSAL IN COMMUNITY: A CROSS SECTIONAL STUDY

    Nov 1, 2019, 00:00

  • PGI38 ASSESSMENT OF PROPULSIVES CONSUMPTION IN UKRAINE IN COMPARISON WITH OTHER COUNTRIES OF THE WORLD

    Nov 1, 2019, 00:00

  • PNS26 USING SURROGATES FOR PREDICTION OVERALL SURVIVAL IN ONCOLOGY: CONSIDERATIONS FOR NEW TREATMENTS AND EARLIER STAGES OF CANCER

    Nov 1, 2019, 00:00

  • Surgery - Organizational Practices

    Nov 1, 2019, 00:00

  • PDG62 THE CONTINUUM OF INTERNATIONAL REFERENCE PRICING USE IN LATIN AMERICA: A QUALITATIVE ANALYSIS

    Nov 1, 2019, 00:00

  • Sensory System Disorders - Economic Evaluation

    Nov 1, 2019, 00:00

  • Cancer - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PMS32 COST MINIMIZATION ANALYSIS OF ZENTIUS FOR THE TREATMENT OF VITAMIN D AND CALCIUM DEFICIENCY IN TURKEY

    Nov 1, 2019, 00:00

  • PCN416 NETWORK META-ANALYSIS FOR SURROGATE ENDPOINT EVALUATION IN ADVANCED COLORECTAL CANCER: A BAYESIAN APPROACH

    Nov 1, 2019, 00:00

  • PCN470 EXPERT CONSENSUS ON PATIENT-REPORTED OUTCOMES FOR THE MANAGEMENT OF PANCREATIC CANCER

    Nov 1, 2019, 00:00

  • PBI47 PAYER AND PRESCRIBER PERSPECTIVES ON CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPIES IN DIFFUSE LARGE B-CELL LYMPHOMA

    Nov 1, 2019, 00:00

  • PIH26 JUVENILE IDIOPATHIC ARTHRITIS IS ASSOCIATED WITH CONSIDERABLE FINANCIAL BURDEN TO SOCIETY: RESULTS OF A DUTCH COST ANALYSIS

    Nov 1, 2019, 00:00

  • PRO88 PAYER AND PHYSICIAN PERSPECTIVES OF CURRENT AND EMERGING SPINAL MUSCULAR ATROPHY TREATMENTS IN THE EU5

    Nov 1, 2019, 00:00

  • PCN225 TWO COST-EFFECTIVENESS ANALYSES OF THE USE OF CARFILZOMIB IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE VERSUS LENALIDOMIDE PLUS DEXAMETHASONE AND CARFILZOMIB PLUS DEXAMETHASONE VERSUS BORTEZOMIB PLUS DEXAMETHASONE FOR THE TREA ...

    Nov 1, 2019, 00:00

  • Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward [Editor's Choice]

    Nov 1, 2019, 00:00

  • PRS3 A SYSTEMATIC REVIEW OF SINGLE-INHALER TRIPLE THERAPY IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

    Nov 1, 2019, 00:00

  • PCN514 REAL WORLD TREATMENT PATHWAYS OF DIFFUSE LARGE B-CELL LYMPHOMA IN GERMAN CLAIMS DATA

    Nov 1, 2019, 00:00

  • PND122 HEALTHCARE RESOURCE UTILIZATIONS AND COSTS AMONG PATIENTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS - A COMPARISON OF PATIENTS WITH AND WITHOUT UPPER LIMB FUNCTION IMPAIRMENT

    Nov 1, 2019, 00:00

  • PMH14 THE BURDEN OF TREATMENT-RESISTANT DEPRESSION: A TARGETED LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PDG26 COST-EFFECTIVENESS OF RANIBIZUMAB VERSUS VERTEPORFIN PHOTODYNAMIC THERAPY IN THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGICAL MYOPIA: FROM CHINESE SOCIETAL PERSPECTIVE

    Nov 1, 2019, 00:00

  • Surgery - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • PDB94 PREDICTIVE MODELS USING MACHINE LEARNING FOR MICROVASCULAR COMPLICATIONS IN PATIENTS WITH TYPE 1 DIABETES: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PIN132 HEALTH-ECONOMIC MODELLING OF INFECTIOUS DISEASE DIAGNOSTICS: CURRENT APPROACHES AND FUTURE OPPORTUNITIES

    Nov 1, 2019, 00:00

  • PMU64 UNLOCKING ACCESS FOR TRANSFORMATIONAL CAR-T CELL AND GENE THERAPIES. ARE BIOSIMILARS THE KEY?

    Nov 1, 2019, 00:00

  • PNS225 CURRENT STATUS OF OUTCOMES-BASED AGREEMENTS IN SELECTED EUROPEAN COUNTRIES AND CANADA

    Nov 1, 2019, 00:00

  • PMU113 IS THERE AN ASSOCIATION BETWEEN ERG AND NICE REIMBURSEMENT RECOMMENDATIONS?

    Nov 1, 2019, 00:00

  • PCN297 ATTRIBUTE DEVELOPMENT FOR A DISCRETE CHOICE EXPERIMENT (DCE) EXPLORING WILLINGNESS TO PAY (WTP) FOR CURING CANCER

    Nov 1, 2019, 00:00

  • PRS54 THE SUITABILITY OF THE EQ-5D-5L IN ASTHMA PATIENTS

    Nov 1, 2019, 00:00

  • PCN119 BUDGET IMPACT OF IXAZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN BRAZIL

    Nov 1, 2019, 00:00

  • PSU13 COST UTILITY ANALYSIS OF ROBOTIC-ASSISTED PARTIAL NEPHRECTOMY VERSUS OPEN RADICAL NEPHRECTOMY IN KOREAN PATIENTS WITH RENAL CANCER

    Nov 1, 2019, 00:00

  • PND97 FACTORS INFLUENCING HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS USING EXPAND TRIAL DATA

    Nov 1, 2019, 00:00

  • PCV109 COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS FOR THE MINIMALLY INVASIVE SUTURELESS AORTIC VALVE REPLACEMENT IN PATIENTS WITH AORTIC STENOSIS IN POLAND

    Nov 1, 2019, 00:00

  • PNS156 CHANGES IN LEADING CAUSES OF DEATHS AND THE NUMBER OF HOSPITAL BEDS IN HUNGARY BETWEEN 2002 AND 2017

    Nov 1, 2019, 00:00

  • PCN399 ASSESSMENT OF SURROGACY OUTCOMES FOR OVERALL SURVIVAL IN ONCOLOGY BASED ON NICE APPRAISALS AND POST-APPRAISAL EVIDENCE

    Nov 1, 2019, 00:00

  • PMU99 REVIEW OF RECENT NICE TECHNOLOGY APPRAISALS USING SIMULATED TREATMENT COMPARISONS

    Nov 1, 2019, 00:00

  • PCV70 HEALTH CARE COST FOR PATIENTS WITH CHRONIC HEART FAILURE AND IRON DEFICIENCY / ANEMIA BEFORE AND AFTER TREATMENT WITH FERRIC CARBOXYMALTOSE

    Nov 1, 2019, 00:00

  • PGI42 THE NEW WAVE OF ULCERATIVE COLITIS BIOLOGICS: CONSTRAINED BY THE COST-CONSCIOUS EUROPEAN MARKETS OR CHALLENGING THE TREATMENT PARADIGM?

    Nov 1, 2019, 00:00

  • PDB21 PREDICTING HEALTHCARE COSTS OF DIABETES USING MACHINE LEARNING MODELS

    Nov 1, 2019, 00:00

  • PND8 A SYSTEMATIC LITERATURE REVIEW OF EFFICACY AND SAFETY OF DISEASE MODIFYING THERAPIES (DMTS) IN SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS

    Nov 1, 2019, 00:00

  • PCN471 ATTITUDE TOWARDS CERVICAL CANCER SCREENING ATTENDANCE AND NON-ATTENDANCE AMONG ROMANY AND NON-ROMANY WOMEN

    Nov 1, 2019, 00:00

  • PMD23 BUDGET IMPACT ANALYSIS OF A BIOSYNTHETIC MESH FOR ABDOMINAL WALL HERNIA REPAIR IN COMPLEX HERNIAS IN GREECE

    Nov 1, 2019, 00:00

  • PCV65 FEE FOR SERVICE VERSUS LUMP SUM PAYMENT: COST-COST MODEL FOR RULING OUT CORONARY ARTERY DISEASE IN GERMANY - PRIVATE INSURANCE VERSUS STATUTORY SICK FUNDS

    Nov 1, 2019, 00:00

  • PCN303 ITALIAN NATIONAL HEALTH SERVICE REIMBURSEMENT POLICY FOR ONCOLOGY DRUGS AFTER CONDITIONAL MARKET AUTHORIZATION GRANTED BY THE EUROPEAN MEDICINE AGENCY: A RETROSPECTIVE ANALYSIS

    Nov 1, 2019, 00:00

  • PCN166 ECONOMIC EVALUATION OF ANTICANCER DRUGS: A SYSTEMATIC REVIEW ON COST-EFFECTIVENESS STUDIES BASED ON HEALTHCARE SYSTEM CLAIMS DATABASES

    Nov 1, 2019, 00:00

  • PNS37 SHOULD WE CONSTANTLY BE COUNTING WITH CONSTANT DISCOUNTING?

    Nov 1, 2019, 00:00

  • PNS345 BUSINESS MODEL INNOVATION OF INTERNET HOSPITALS IN CHINA: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • Neurological Disorders - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PCN29 COMPARATIVE EFFICACY OF NIVOLUMAB VERSUS RELEVANT TREATMENTS IN PRETREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A SYSTEMATIC LITERATURE REVIEW AND INDIRECT TREATMENT COMPARISON OF RANDOMIZED CONTROLLED TRIALS (RCTS)

    Nov 1, 2019, 00:00

  • PCN62 COMPARISON OF NETWORK META-ANALYSES USING STANDARD, MIXTURE CURE AND SPLINE MODELS

    Nov 1, 2019, 00:00

  • PCN124 BUDGET IMPACT ANALYSIS OF IMMUNOTHERAPY AS SECOND-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) AT MEXICO´S NATIONAL INSTITUTE OF CANCER

    Nov 1, 2019, 00:00

  • PSU19 ROBOTIC ASSISTED GASTRECTOMY COMPARED WITH OPEN RESECTION: A CASE-MATCHED STUDY OF CLINICAL OUTCOMES AND COST-EFFECTIVENESS

    Nov 1, 2019, 00:00

  • PUK11 TOLVAPTAN REDUCES HEALTHCARE BURDEN IN PATIENTS WITH STAGE 1-3 ADPKD IN SPAIN

    Nov 1, 2019, 00:00

  • PDG10 IMPROVING THE BUSINESS MODEL OF VALUE ADDED MEDICINES: NEW VALUE ASSESSMENT FRAMEWORK IS NEEDED

    Nov 1, 2019, 00:00

  • PDG3 ANTI-VEGF DRUGS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION - A SYSTEMATIC REVIEW OF THE IMPACT OF ANTI-VEGF THERAPY ON REDUCING BLINDNESS AND VISUAL IMPAIRMENT

    Nov 1, 2019, 00:00

  • PCV38 HEALTH OUTCOMES PROJECTIONS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF HEART FAILURE IN A REAL-WORLD POPULATION IN PORTUGAL

    Nov 1, 2019, 00:00

  • Drugs Generics - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PDB68 ASSESSMENT OF RISK FOR DEVELOPMENT OF TYPE 2 DIABETES IN THE GREEK POPULATION

    Nov 1, 2019, 00:00

  • PND6 CLINICALLY RELEVANT REDUCTION OF MIGRAINE SYMPTOMS BY FREMANEZUMAB IN PATIENTS WITH UP TO ONE PREVENTIVE MIGRAINE PROPHYLAXIS TREATMENT IN THE PAST

    Nov 1, 2019, 00:00

  • PND17 SELECTING APPROPRIATE OUTCOME MEASURES FOR ALS CLINICAL TRIALS

    Nov 1, 2019, 00:00

  • PNS272 AMNOG BENEFIT ASSESSMENT IN GERMANY AND ITS IMPACT ON PRICE NEGOTIATIONS

    Nov 1, 2019, 00:00

  • PDG22 THE ECONOMIC IMPACT OF SERIOUS FLUOROQUINOLONE-RELATED ADVERSE EVENTS

    Nov 1, 2019, 00:00

  • PNS212 AIFA'S NEW INNOVATIVENESS DESIGNATION: DRIVERS FOR AWARD AND COMPARISON TO FRENCH HTA ASSESSMENTS

    Nov 1, 2019, 00:00

  • PMS31 COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB IN ANKYLOSING SPONDYLITIS IN BIOLOGIC-NAIVE PATIENTS FROM THE PORTUGUESE PERSPECTIVE

    Nov 1, 2019, 00:00

  • PMU141 DEVELOPMENT OF EQ-5D-5L BOLT-ONS FOR COGNITION AND VISION

    Nov 1, 2019, 00:00

  • PCN241 COSTS OF CYTOKINE RELEASE SYNDROME (CRS) AND NEUROLOGICAL EVENTS (NE) IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA RECEIVING LISOCABTAGENE MARALEUCEL (LISO-CEL) IN THE TRANSCEND NHL 001 CLINICAL TRIAL: A MICRO-COSTING ST ...

    Nov 1, 2019, 00:00

  • PUK8 THE ECONOMIC IMPACT AND VARIABILITY OF MANAGING DISTRAL RENAL TUBULAR ACIDOSIS (DRTA) IN THE UK HEALTHCARE SETTING

    Nov 1, 2019, 00:00

  • PNS55 THE COST OF MEDICATION ERRORS IN PUBLIC HEALTH FACILITIES OF EASTERN REGION, GHANA.

    Nov 1, 2019, 00:00

  • Methodological and Conceptual Studies

    Nov 1, 2019, 00:00

  • Individual's Health - Patient-Centered Research

    Nov 1, 2019, 00:00

  • CL2 SYSTEMATIC REVIEW AND METANALYSIS ON THE IMPACT OF MULTI-DRUG RESISTANT BACTERIA ON ECONOMIC AND CLINICAL OUTCOMES OF HEALTHCARE ACQUIRED INFECTIONS

    Nov 1, 2019, 00:00

  • PCN466 HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN CLINICAL PRACTICE FOR IMMUNE-CHECKPOINT INHIBITORS (ICI)-TREATED PATIENTS: WHAT ARE PATIENTS' EXPERIENCES AND EXPECTATIONS? RESULTS FROM AN ONLINE PATIENT COMMUNITY RESEARCH

    Nov 1, 2019, 00:00

  • PIN149 RETROSPECTIVE SURVEY FOR HEPATITIS B VIRUS REACTIVATION DURING IMMUNOSUPPRESSIVE THERAPIES FOR RHEUMATOID WITH ADMINISTRATIVE DATA

    Nov 1, 2019, 00:00

  • PCN322 TREATMENT OF ADVANCED BILIARY TRACT CANCER (BTC) AFTER PROGRESSION ON FIRST-LINE (1L) SYSTEMIC THERAPY

    Nov 1, 2019, 00:00

  • PSY57 PATTERNS OF PHARMACOLOGICAL TREATMENT IN ADULT PATIENTS WITH ATOPIC DERMATITIS

    Nov 1, 2019, 00:00

  • PIN151 PATIENTS TREATED FOR HEPATITIS C: AN OBSERVATIONAL STUDY WITH THE FRENCH ADMINISTRATIVE HEALTH CARE DATABASE (SNDS)

    Nov 1, 2019, 00:00

  • PMD10 INSIGHTS INTO THE IMPACT OF POINT-OF-CARE TESTING: A SYSTEMATIC REVIEW OF HEALTH-ECONOMIC EVALUATIONS

    Nov 1, 2019, 00:00

  • PND103 BURDEN OF COMORBID DEPRESSION AND ANXIETY ON WORK PRODUCTIVITY IN ADULT MIGRAINE PATIENTS IN THE UNITED STATES

    Nov 1, 2019, 00:00

  • PMH18 PREVENTING MENTAL HEALTH CONDITIONS IN CHILDREN AND YOUNG ADULTS: A REVIEW OF THE COSTS OF COMPLEX INTERVENTIONS

    Nov 1, 2019, 00:00

  • PDB113 THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE AND LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): PATIENT-REPORTED OUTCOMES AT BASELINE

    Nov 1, 2019, 00:00

  • PMU145 SYSTEMATIC REVIEW OF PAEDIATRIC ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION: DONOR AVAILABILITY, QUALITY OF LIFE AND ECONOMIC IMPLICATIONS

    Nov 1, 2019, 00:00

  • PRO19 THE ROLE PLAYED BY SOCIAL COSTS IN ECONOMIC EVALUATIONS OF RARE DISEASE INTERVENTIONS

    Nov 1, 2019, 00:00

  • PMS2 EXAMINATION OF A SPORT-SPECIFIC DYNAMIC CORE STABILITY PROGRAMME AMONG FEMALE ACROBATIC ROCK AND ROLL DANCERS

    Nov 1, 2019, 00:00

  • PCN38 IMPACT OF CERVICAL CANCER SCREENING TIME ON SURGICAL OUTCOMES

    Nov 1, 2019, 00:00

  • PCN33 ADJUSTED COMPARISON OF DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE (DVD) VERSUS LENALIDOMIDE PLUS DEXAMETHASONE (RD) IN SECOND LINE (2L) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) PATIENTS, USING INDIVIDUAL PATIENT LEVEL DATA (IPD) ...

    Nov 1, 2019, 00:00

  • PSY7 INDIRECT COST BURDEN OF MODERATE-TO-SEVERE PSORIASIS IN EU5 AND THE SAVINGS GENERATED BY CHOOSING GUSELKUMAB OVER ADALIMUMAB

    Nov 1, 2019, 00:00

  • PCN213 COST-UTILITY ANALYSIS OF ABIRATERONE IN THE TREATMENT OF DOCETAXEL-REFRACTORY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER COMPARED TO BEST SUPPORTIVE CARE IN IRAN

    Nov 1, 2019, 00:00

  • PCV72 CLINICAL AND ECONOMIC IMPLICATIONS OF USING NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS FOR NON-VALVULAR ATRIAL FIBRILLATION USING AVAILABLE EVIDENCE FROM REAL-WORLD EXPERIENCE

    Nov 1, 2019, 00:00

  • Neurological Disorders - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PMU135 PATIENT-REPORTED OUTCOME MEASURES IN PATIENTS WITH CHRONIC OCULAR SURFACE PAIN : A LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PCN341 HOW INFLUENTIAL IS BUDGET IMPACT IN DETERMINING PRICING FOR ONCOLOGY PRODUCTS?: A REGRESSION ANALYSIS

    Nov 1, 2019, 00:00

  • NO Specific Disease - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PRS55 PREDICTING THE RISK OF IN-HOSPITAL MORTALITY IN ADULT COMMUNITY-ACQUIRED PNEUMONIA PATIENTS WITH MACHINE LEARNING: A RETROSPECTIVE ANALYSIS OF ROUTINELY COLLECTED HEALTH DATA

    Nov 1, 2019, 00:00

  • PRO58 CLINICAL AND ECONOMIC BURDEN OF TRANSFUSION-DEPENDENT BETA-THALASSEMIA IN FRANCE: A RETROSPECTIVE ANALYSIS OF THE FRENCH NATIONAL HEALTH DATA SYSTEM (SNDS)

    Nov 1, 2019, 00:00

  • PBI43 THE IMPACT OF BIOSIMILAR PRICE CONTAGION ON NEW INNOVATION IN INFLAMMATORY DISEASES

    Nov 1, 2019, 00:00

  • PIN127 BIRTH COHORT SCREENING FOR HEPATITIS C: A SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS

    Nov 1, 2019, 00:00

  • PCN137 COST COMPARISON OF ADVERSE EVENTS AND TREATMENT ADMINISTRATION OF LURBINECTEDIN VERSUS INTRAVENOUS TOPOTECAN FOR RELAPSED SMALL CELL LUNG CANCER IN SPAIN AND THE UNITED KINGDOM

    Nov 1, 2019, 00:00

  • PCN61 A FREELY AVAILABLE GENERIC COST-EFFECTIVENESS MODEL IN ONCOLOGY FOR EARLY-STAGE DECISION MAKING

    Nov 1, 2019, 00:00

  • PCN508 A COMPARISON OF PATIENT CHARACTERISTICS TREATED WITH NIVOLUMAB FOR RECURRENT/METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) IN GERMANY AND THE USA

    Nov 1, 2019, 00:00

  • PRO122 ECONOMIC EVALUATION OF NUSINERSEN IN SPINAL MUSCULAR ATROPHY: A COMPARISON OF NICE AND HAS OPINIONS

    Nov 1, 2019, 00:00

  • PSS9 DRUG UTILIZATION AND COSTS OF INTRAVITREAL INJECTED ANTIVEGFS IN ITALY

    Nov 1, 2019, 00:00

  • PIN63 COST-EFFECTIVENESS ANALYSIS OF POSACONAZOLE VERSUS VORICONAZOLE FOR THE PROPHYLAXIS OF INVASIVE FUNGAL DISEASE IN CHINA

    Nov 1, 2019, 00:00

  • PNS369 RECOMMENDATIONS FOR CONDUCTING COGNITIVE INTERVIEWS REMOTELY TO DEVELOP CLINICAL OUTCOME ASSESSMENTS

    Nov 1, 2019, 00:00

  • PNS385 USING THE VARK MODEL TO AID QUALITATIVE DATA COLLECTION IN PEDIATRIC PATIENTS

    Nov 1, 2019, 00:00

  • RW4 APPLICATION OF ARTIFICIAL INTELLIGENCE AND MEDICAL BIG-DATA IN REAL WORLD EVIDENCE GENERATION: A LITERATURE REVIEW OF RESEARCH PRACTICE IN CHINA

    Nov 1, 2019, 00:00

  • PIH60 PEDIATRIC PATIENT ENGAGEMENT: USING PATIENT INSIGHTS TO IMPROVE STUDY DESIGN

    Nov 1, 2019, 00:00

  • PCN453 MODELING THE IMPACT OF NEXT GENERATION SEQUENCING BASED COMPREHENSIVE GENOMIC PROFILING PANEL ON TREATMENT PRACTICES IN ADVANCED OR METASTATIC CANCER

    Nov 1, 2019, 00:00

  • PNS106 FACTORS AFFECTING THE HEALTHCARE PROVIDERS KNOWLEDGE OF PROJECT MANAGEMENT

    Nov 1, 2019, 00:00

  • PND89 NEGATIVE HTA RECOMMENDATIONS FOR MEDICINES IN NEUROLOGY THERAPEUTIC AREAS – FOURFOLD HIGHER ODDS IN POLAND COMPARED WITH THE UNITED KINGDOM

    Nov 1, 2019, 00:00

  • PIH24 COST-UTILITY ANALYSIS OF NEWBORN SCREENING PROGRAM BY TANDEM MASS SPECTROMETRY IN JAPAN

    Nov 1, 2019, 00:00

  • PNS372 A SIMULATION STUDY COMPARING THE PERFORMANCE OF DISCRETE CHOICE EXPERIMENT AND SWING WEIGHTING FOR ELICITATION OF PREFERENCES

    Nov 1, 2019, 00:00

  • PDG65 THE IMPACT OF OUT-OF-POCKET SPENDING ON THE PENETRATION OF GENERIC DRUGS AFTER THE EXPIRY OF THE MARKET EXCLUSIVITY

    Nov 1, 2019, 00:00

  • Systemic Disorders/Conditions - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PMH54 IS THE OXCAP-MH CAPABILITY MEASURE A FEASIBLE AND PSYCHOMETRICALLY VALID TOOL FOR THE ROUTINE EVALUATION OF MENTAL HEALTH SERVICES?

    Nov 1, 2019, 00:00

  • PCN418 ASSESSMENT OF STUDIES EVALUATING INCREMENTAL COSTS, EFFECTIVENESS OR COST-EFFECTIVENESS OF SYSTEMIC THERAPIES IN BREAST CANCER BASED ON CLAIMS DATA: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PCN158 PATIENT BURDEN AND COSTS FOR THE TREATMENT OF MULTIPLE MYELOMA IN FINLAND IN 2009-2016, USING MULTIPLE DATA SOURCES: AN ELECTRONIC HOSPITAL DATABASE, MEDICAL CHART REVIEW, AND INTERVIEWS WITH HEALTHCARE PROFESSIONALS

    Nov 1, 2019, 00:00

  • PCN170 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB IN THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN ITALY

    Nov 1, 2019, 00:00

  • PCN343 INVESTIGATING EUROPEAN HTA AND PRICING FOR HISTOLOGY-AGNOSTIC TREATMENTS

    Nov 1, 2019, 00:00

  • PGI47 PSYCHOMETRIC VALIDATION OF THE INTESTINAL GAS QUESTIONNAIRE (IGQ) FOR MEASURING GAS RELATED SYMPTOMS AND THEIR IMPACT ON DAILY LIFE

    Nov 1, 2019, 00:00

  • PNS346 CAN META-ANALYSES HELP IN SYNTHESIZING DATA ACROSS HEALTH ECONOMIC STUDIES?

    Nov 1, 2019, 00:00

  • Multiple Diseases - Economic Evaluation

    Nov 1, 2019, 00:00

  • PCN302 NEW DRG-BASED REIMBURSEMENT OF RADIATION THERAPY AT RUSSIAN HOSPITALS

    Nov 1, 2019, 00:00

  • PIH14 INCREMENTAL COSTS OF PREMATURITY AND LOW BIRTHWEIGHT

    Nov 1, 2019, 00:00

  • NO Specific Disease - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PCN334 ESTIMATING DIRECT COSTS AND PRODUCTIVITY COSTS ASSOCIATED WITH RAPID INFUSION OF DARATUMUMAB

    Nov 1, 2019, 00:00

  • Impact of Star Rating Medication Adherence Measures on Adherence for Targeted and Nontargeted Medications

    Nov 1, 2019, 00:00

  • PIN37 HEALTH AND ECONOMIC BURDEN ASSOCIATED WITH 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE SEROTYPES IN CHILDREN IN THREE EUROPEAN COUNTRIES

    Nov 1, 2019, 00:00

  • PMS58 HEALTH TECHNOLOGY ASSESSMENT (HTA) OF EQUISTASI FOR THE TREATMENT OF PATIENTS WITH PARKINSONIAN POST-DYSKINESIA FALLS.

    Nov 1, 2019, 00:00

  • PMU116 NICE MEDICAL TECHNOLOGIES GUIDANCE: IMPACT BEYOND THE UK

    Nov 1, 2019, 00:00

  • PND23 HEALTHCARE EXPENDITURES ASSOCIATED WITH ADHERENCE TO ANTIDEPRESSANT MEDICATION MANAGEMENT MEASURES DURING ACUTE AND CONTINUATION PHASES OF DEPRESSION TREATMENT AMONG OLDER ADULTS WITH DEMENTIA AND MAJOR DEPRESSIVE DISORDER

    Nov 1, 2019, 00:00

  • PNS155 ACCESS OF BULGARIAN PATIENTS TO BIOSIMILAR MEDICINES

    Nov 1, 2019, 00:00

  • PCN122 COST-EFFECTIVENESS ANALYSIS OF TRASUTUZUMAB EMTANSINE VERSUS TRASTUZUMAB FOR WOMEN WITH HER2+ ADJUVANT BREAST CANCER IN FRANCE

    Nov 1, 2019, 00:00

  • PMS4 EFFICACY OF RENAL FUNCTION IN PATIENTS WITH EARLY DIABETIC NEPHROPATHY COMPLICATED WITH HYPERURICEMIA.

    Nov 1, 2019, 00:00

  • Individual's Health - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PND131 HOW WELL ARE MULTIPLE SCLEROSIS PATIENTS INFORMED ABOUT THEIR DISEASE AND THEIR TREATMENT: AN ANALYSIS OF DATA COLLECTED BY A NOVEL MOBILE APPLICATION (MS GEMEINSAM)

    Nov 1, 2019, 00:00

  • PCN449 AN ANALYSIS OF EQ-5D ADJUSTING FOR TREATMENT SWITCHING: THE CASE OF PATIENTS WITH EGFR T790M POSITIVE NSCLC TREATED WITH OSIMERTINIB

    Nov 1, 2019, 00:00

  • PSY18 COST-EFFECTIVENESS OF TOFACITINIB IN ACTIVE PSORIATIC ARTHRITIS AFTER ANTI-TUMOUR NECROSIS FACTOR (ANTI-TNF) FAILURE OR INTOLERANCE IN SPAIN

    Nov 1, 2019, 00:00

  • PIN46 CONTRASTING AVAILABLE THERAPY FOR PATIENTS WITH LIMITED OPTIONS DUE TO EXTREMELY DRUG-RESISTANCE BACTERIA WITH A NOVEL OPTION FOR COMPLICATED NOSOCOMIAL INFECTIONS

    Nov 1, 2019, 00:00

  • PMS10 COMPARATIVE ANALYSIS OF HIP PROSTHESIS BY REVISION METHODS FOR LATERAL AND DIRECT ANTERIOR APPROACH

    Nov 1, 2019, 00:00

  • PCN402 THE CLINICAL AND ECONOMIC CONSEQUENCES OF DELAYS IN REIMBURSEMENT FOR SELECT NOVEL CANCER THERAPEUTICS IN CANADA, ITALY, AND AUSTRALIA

    Nov 1, 2019, 00:00

  • PIT3 PROGNOSTIC FACTORS FOR POOR RECOVERY AFTER TRAUMA: A PROSPECTIVE MULTICENTRE COHORT STUDY

    Nov 1, 2019, 00:00

  • PCN245 GRADE 3/4 ADVERSE EVENT (AE) COSTS OF NIVOLUMAB VERSUS DABRAFENIB + TRAMETINIB AS ADJUVANT TREATMENT IN PATIENTS WITH STAGE III BRAF-MUTATED CUTANEOUS MELANOMA IN PORTUGAL

    Nov 1, 2019, 00:00

  • PDG45 5 YEAR STATUS OF RISK SHARING AGREEMENT IN KOREA SINCE THE IMPLEMENTATION

    Nov 1, 2019, 00:00

  • PRO110 A STRUCTURED REVIEW OF NICE AND SMC APPRAISALS IN ORPHAN GENETIC NEUROLOGICAL DISEASES: ECONOMIC AND CLINICAL UNCERTAINTIES AND HOW TO ADDRESS THEM

    Nov 1, 2019, 00:00

  • PIH4 SUPPORTING THE CONTENT VALIDITY OF THE MENSTRUAL PICTOGRAM SUPER-ABSORBENT POLYMERS CONTAINING VERSION 3 (MP SAP-C V3) USING DATA FROM COGNITIVE INTERVIEWS (CIS) OF WOMEN WITH UTERINE FIBROIDS (UF)

    Nov 1, 2019, 00:00

  • PCN179 TREOSULFAN-BASED CONDITIONING VS BUSULFAN-BASED CONDITIONING FOR ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH AML OR MDS — A UK COST-UTILITY ANALYSIS

    Nov 1, 2019, 00:00

  • Gastrointestinal Disorders - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PIN21 THE ECONOMIC IMPACT OF TRICLOSAN-COATED SUTURES IN WOUND CLOSURE: A BUDGET IMPACT ANALYSIS FROM HOSPITAL PERSPECTIVE IN ITALY

    Nov 1, 2019, 00:00

  • PIN152 ECONOMIC IMPACT OF SEQUELAE RELATED TO INVASIVE MENINGOCOCCAL DISEASE IN A FRENCH REAL-WORLD SETTING

    Nov 1, 2019, 00:00

  • MT3 OUTCOMES AND HOSPITAL UTILIZATION OF SLEEP APNEA PATIENTS TREATED WITH POSITIVE AIRWAY PRESSURE DURING AND AFTER ONSET OF HEART FAILURE

    Nov 1, 2019, 00:00

  • Cancer - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PND2 INDIRECT COMPARISON OF THE EFFICACY OF FREMANEZUMAB VERSUS ERENUMAB IN EPISODIC MIGRAINE PATIENTS WHO HAD FAILED 2-4 PRIOR MIGRAINE PREVENTIVE TREATMENTS

    Nov 1, 2019, 00:00

  • PCN19 RELATIONSHIP OF STATIN OR ANTI PLATELET AGENTS AND HEPATOCELLULAR CARCINOMA IN TREATMENT NAIVE PATIENTS WITH CHB

    Nov 1, 2019, 00:00

  • PRO140 KNOWLEDGE, USE AND DESIDERATA ABOUT INFORMATION AND COMMUNICATION TECHNOLOGIES SYSTEMS FOR SYSTEMIC LUPUS ERYTHEMATOSUS. PRELIMINARY RESULTS FROM THE INTEGRATE PILOT PROJECT.

    Nov 1, 2019, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PCN237 IMPACT OF ORAL TARGETED THERAPY ON THE ECONOMIC BURDEN OF CLL IN CANADA

    Nov 1, 2019, 00:00
  • «
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49 (current)
  • 50
  • »